Cerevance Doses First Subject in Phase 1 Clinical Study of CVN293, a Selective Inhibitor of KCNK13 Designed to Selectively Modulate Neuroinflammation, for the Treatment of ALS and Alzheimer’s Disease

2 years ago

BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on advancing novel,…

Certara Announces 300th Regulatory Submission Milestone Using its Technology-enabled Services and Software

2 years ago

Dedicated team of global regulatory experts delivers submissions in increasingly shorter timelinesPRINCETON, N.J., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Certara,…

Panbela to Present at the LD Micro Investor Conference

2 years ago

MINNEAPOLIS, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the…

IN8bio Strengthens Intellectual Property Portfolio with Newly Granted Global Patents

2 years ago

Newly granted patents expand the use of the DeltEx Drug Resistant Immunotherapy (DRI) platform to encompass Chimeric Antigen Receptor T-cell…

Rhythm Pharmaceuticals Receives Orphan Drug Designation from European Medicines Agency for Setmelanotide for Treatment of Acquired Hypothalamic Obesity

2 years ago

BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the…

Assure Holdings Corp. Announces Exploration of Strategic Alternatives

2 years ago

DENVER, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”) (NASDAQ: IONM), a provider of intraoperative…

Icosavax to Participate in the Cantor Fitzgerald Global Healthcare Conference 2023

2 years ago

SEATTLE, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP)…

BioVie to Participate in the Cantor Fitzgerald Global Healthcare Conference

2 years ago

CARSON CITY, Nev., Sept. 19, 2023 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company…

Akoya Biosciences Sets a New Standard for Scaling Spatial Biology with the Launch of 2.0 Platforms

2 years ago

PhenoCycler-Fusion 2.0 enhancements enable the highest throughput workflow for spatial discovery studies.PhenoImager HT 2.0 delivers a 5x greater speed improvement…